The use of infliximab in patients with a deceased donor kidney transplant led to increased infections and did not improve allograft survival, according to data presented at the American Transplant Congress.
“The intervention had no effect on allograft function or acute rejection,” Peter S. Heeger, MD, a professor of medicine and immunology at the Icahn School of Medicine at Mount Sinai Medical Center in New York, told Healio. “Unexpectedly, we observed higher rates of infection with the BK virus, a virus that can contribute to graft dysfunction and graft loss.”
Read the full article in Healio.